中国网财经12月25日讯 日前,凡舒卓(Fasenra,本瑞利珠单抗注射液)新适应症获国家药品监督管理局(NMPA)批准,用于治疗成人嗜酸性肉芽肿性多血管炎(EGPA)。此次获批是基于早前发表在《新英格兰医学杂志》上的MANDARA全球III期临床研究结果,该研究是首个针对复发/难治性EGPA的生物制剂非劣效性头对头研究,比较了本瑞利珠单抗与此前唯一获批治疗EGPA的生物制剂美泊利珠单抗在复发/...
Source Link中国网财经12月25日讯 日前,凡舒卓(Fasenra,本瑞利珠单抗注射液)新适应症获国家药品监督管理局(NMPA)批准,用于治疗成人嗜酸性肉芽肿性多血管炎(EGPA)。此次获批是基于早前发表在《新英格兰医学杂志》上的MANDARA全球III期临床研究结果,该研究是首个针对复发/难治性EGPA的生物制剂非劣效性头对头研究,比较了本瑞利珠单抗与此前唯一获批治疗EGPA的生物制剂美泊利珠单抗在复发/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.